XORTX Therapeutics Inc : XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
XORTX Therapeutics Inc. (XRTX) announced submission of a new patent for the treatment of chronic kidney disease. The patent entitled "Oral and Sublingual Formulations of Xanthine Oxidase Inhibitors and Methods of Treating Disease" outlines new formulations and methods for safer and more effective the use of xanthine oxidase inhibitors in the setting of chronic kidney disease in particular autosomal dominant polycystic kidney disease, diabetic nephropathy, IgA nephropathy, lupus nephritis and focal segmental glomerulosclerosis.
By Robb M. Stewart XORTX Therapeutics' shares jumped Wednesday after the Canadian pharmaceutical company submitted a new patent for the treatment of chronic.
Fentanyl: a potent opioid that has been making headlines in recent years. But have you ever wondered when this powerful drug found its way into the US market? Delve into the gripping history of Fentanyl as we uncover the crucial moments that led to its availability in the United States.In brief, Fentanyl’s journey in the […]